- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04460105
Lanadelumab in Participants Hospitalized With COVID-19 Pneumonia
October 9, 2020 updated by: Shire
A Phase 1b, Randomized, Double-blind, Single and Repeat Dosing Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Lanadelumab When Added to Standard-of-Care in Subjects Hospitalized With COVID-19 Pneumonia
The purpose of this study is to evaluate the safety, pharmacokinetic and pharmacodynamics of lanadelumab administered by intravenous (IV) infusion when added to standard-of-care (SoC) in adults hospitalized with COVID-19 pneumonia.
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Detailed Description
This study consists of two cohorts (Cohort 1 [Single-dose Cohort], and Cohort 2 [Repeat-dose Cohort]).
Up to approximately 24 participants will be enrolled in this study, in which up to 12 participants may be enrolled into Cohort 1.
However, Cohort 1 will be closed upon implementation of Amendment 2. Approximately 12 participants will be enrolled in Cohort 2. Participants will be randomized in 3:1 ratio (9 lanadelumab: 3 placebo) in each Cohort.
Study Type
Interventional
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Males and females 18 years of age or older at the time of signing of the informed consent form (ICF).
Hospitalized with evidence of COVID-19 pneumonia defined as:
- Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection documented with polymerase chain reaction (PCR) of any specimen; e.g. respiratory, blood, urine, stool, other body fluid
- Presence of respiratory distress as indicated by peripheral capillary oxygen saturation (SpO2) lesser than or equal to (=<) 93 percent (%) on room air or respiratory rate greater than or equal to (>=) 30 breaths per minute (breaths/min).
- The participant (or a legally acceptable representative) has provided written informed consent approved by the institutional review board (IRB)/ independent ethics committee (IEC) before any study-specific procedures are performed.
- Agree to adhere to the protocol-defined schedule of treatments, assessments, and procedures.
Exclusion Criteria:
- Invasive mechanical ventilation (IMV) extracorporeal membrane oxygenation (ECMO) or with evidence of severe respiratory distress such that IMV/ECMO is imminent within 12 hours of randomization.
- Where, in the opinion of the investigator, progression to death is imminent and inevitable within the next 24 hours, irrespective of the provision of treatments.
- Requiring vasopressor support (use of fluid support is not exclusionary)
- Known or suspected venous thromboembolism.
- Known or suspected hypersensitivity to lanadelumab or any of its excipients.
- Dosing with an investigational drug or exposure to an investigational device within 4 weeks prior to screening.
- Previous (within 3 months of screening) or current use of immunomodulators (e.g. methotrexate, azathioprine, 6-mercaptopurine, tumor necrosis factor [TNF] alpha inhibitor, Janus kinase [JAK] inhibitor, alpha-integrin).
- Previous (within 3 months of screening) or current use of plasma kallikrein inhibitor or bradykinin receptor blocker.
- Use of supplemental oxygen for a medical condition prior to receiving COVID-19 diagnosis.
- Previously diagnosed with acquired immunodeficiency syndrome (AIDS).
- Active tuberculosis or clinical suspicion of latent tuberculosis.
Any of the following laboratory abnormalities at screening:
- Hemoglobin <= 8 grams per deciliter (g/dL)
- White blood cells <= 3000/ microliters (μL)
- Platelets <= 75,000/μL
- Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >= 3×upper limit of normal (ULN); alkaline phosphatase (ALP) >= 3×ULN; or total bilirubin greater than (>) 2×ULN (unless the bilirubin elevation is a result of Gilbert's syndrome)
- Creatinine >= 2×ULN
- Pregnant or breastfeeding.
- Any significant condition (any surgical or medical condition) that, in the opinion of the investigator or sponsor, may compromise their safety or compliance, preclude the successful conduct of the study, or interfere with interpretation of the results (e.g. significant pre-existing illness or other major comorbidities that the investigator considers may confound the interpretation of study results).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Lanadelumab
Participants receive 300 milligram (mg) of lanadelumab intravenous (IV) infusion on Day 1 during Cohort 1 (single dose cohort) and on Day 1 and Day 4 during Cohort 2 (repeat-dose cohort).
|
Participants will receive 300 mg of lanadelumab IV infusion on Day 1 and Day 4.
Other Names:
|
Placebo Comparator: Placebo
Participants will receive placebo matching IV infusion on Day 1 during Cohort 1 (single dose cohort) and on Day 1 and Day 4 during Cohort 2 (repeat-dose cohort).
|
Participants will receive placebo matching IV infusion on Day 1 and Day 4.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants with Treatment emergent adverse events (TEAEs)
Time Frame: From start of study drug administration to follow-up (up to Day 29)
|
Treatment-emergent adverse events are defined as Adverse events (AEs) with onset at the time of or following the start of treatment with study medication, or medical conditions present prior to the start of treatment but increasing in severity or relationship at the time of or following the start of treatment.
SAE is any untoward clinical manifestation of signs, symptoms or outcomes (whether considered related to investigational product or not and at any dose: results in death, is lifethreatening, requires inpatient hospitalization or prolongation of hospitalization, results in persistent or significant disability/incapacity, congenital abnormality/birth defect, an important medical event.
AESI will include hypersensitivity reactions, events of disordered coagulation such as bleeding AESI, hypercoagulable AESI.
Number of participants with TEAEs including AESI and SAE will be assessed.
|
From start of study drug administration to follow-up (up to Day 29)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetic (PK) Plasma Concentrations of Lanadelumab
Time Frame: Single-dose Cohort: Pre-dose, 1, 24, 72, 144, 216, 336 hours post-dose; Repeat-dose Cohort: Pre-dose, 1, 24, 72, 73, 144, 216, 336 hours post-dose
|
Pharmacokinetic plasma concentrations of lanadelumab after a single and repeat intravenous (IV) doses will be assessed.
|
Single-dose Cohort: Pre-dose, 1, 24, 72, 144, 216, 336 hours post-dose; Repeat-dose Cohort: Pre-dose, 1, 24, 72, 73, 144, 216, 336 hours post-dose
|
Percentage Change from Baseline in Plasma Kallikrein Activity (pKal)
Time Frame: Single-dose Cohort: Pre-dose, 1, 24, 72, 144, 216, 336 hours post-dose; Repeat-dose Cohort: Pre-dose, 72, 144, 216, 336 hours post-dose
|
Percentage change from baseline in pKal activity to assess pharmacodynamics (PD) of lanadelumab.
|
Single-dose Cohort: Pre-dose, 1, 24, 72, 144, 216, 336 hours post-dose; Repeat-dose Cohort: Pre-dose, 72, 144, 216, 336 hours post-dose
|
Percentage Change from Baseline in Cleaved High Molecular Weight Kininogen (cHMWK)
Time Frame: Single-dose Cohort: Pre-dose, 1, 24, 72, 144, 216, 336 hours post-dose; Repeat-dose Cohort: Pre-dose, 72, 144, 216, 336 hours post-dose
|
Percentage change from baseline in cHMWK levels to assess PD of lanadelumab.
|
Single-dose Cohort: Pre-dose, 1, 24, 72, 144, 216, 336 hours post-dose; Repeat-dose Cohort: Pre-dose, 72, 144, 216, 336 hours post-dose
|
Percentage Change from Baseline in Functional C1-Inhibitor (C1-INH)
Time Frame: Single-dose Cohort: Pre-dose, 1, 24, 72, 144, 216, 336 hours post-dose; Repeat-dose Cohort: Pre-dose, 72, 144, 216, 336 hours post-dose
|
Percentage change from baseline in functional C1-INH levels to assess PD of lanadelumab.
|
Single-dose Cohort: Pre-dose, 1, 24, 72, 144, 216, 336 hours post-dose; Repeat-dose Cohort: Pre-dose, 72, 144, 216, 336 hours post-dose
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
October 31, 2020
Primary Completion (Anticipated)
January 27, 2021
Study Completion (Anticipated)
January 27, 2021
Study Registration Dates
First Submitted
June 30, 2020
First Submitted That Met QC Criteria
July 6, 2020
First Posted (Actual)
July 7, 2020
Study Record Updates
Last Update Posted (Actual)
October 12, 2020
Last Update Submitted That Met QC Criteria
October 9, 2020
Last Verified
October 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TAK-743-1002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Yes
IPD Plan Description
Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5).
These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
IPD Sharing Access Criteria
IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/.
For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
IPD Sharing Supporting Information Type
- Study Protocol
- Statistical Analysis Plan (SAP)
- Informed Consent Form (ICF)
- Clinical Study Report (CSR)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19 Pneumonia
-
Ministry of Health, KuwaitUnknownPneumonia, Viral | Moderate COVID-19 Pneumonia, Severe COVID-19 PneumoniaKuwait
-
Mahidol UniversityThe Government Pharmaceutical OrganizationCompletedPneumonia, Viral | Covid-19 | SARS Pneumonia | Covid-19 VaccineThailand
-
Institute of Vaccines and Medical Biologicals,...National Institute of Hygiene and Epidemiology, Vietnam; Hanoi Medical University and other collaboratorsCompletedPneumonia, Viral | COVID-19 Vaccine | COVID-19 Disease | SARS PneumoniaVietnam
-
Patrick RobinsonRecruitingCovid19 | COVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Acute BronchitisUnited States
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
Medical University of LodzRecruitingCOVID-19 | COVID-19 Pneumonia | COVID-19 Respiratory InfectionPoland
-
Fundacion Clinica Valle del LiliUniversidad Autonoma de OccidenteCompletedCOVID-19 Pneumonia | COVID-19 (Coronavirus Disease 2019)Colombia
-
Texas Tech University Health Sciences Center, El...RecruitingPneumonia, Viral | COVID-19 Pneumonia | COVID-19 Respiratory InfectionUnited States
-
Administracion Nacional de Laboratorios e Institutos...RecruitingCovid19 | COVID-19 Pneumonia | COVID-19 Respiratory InfectionArgentina
-
Fondazione Policlinico Universitario Agostino Gemelli...CompletedCovid19 | COVID-19 Pneumonia | COVID-19 Respiratory InfectionItaly
Clinical Trials on Lanadelumab
-
TakedaCompletedHereditary Angioedema (HAE)China
-
Radboud University Medical CenterTakedaCompleted
-
TakedaTakeda Development Center Americas, Inc.Completed
-
TakedaRecruitingHereditary Angioedema (HAE)Japan
-
ShireCompleted
-
ShireCompletedHereditary AngioedemaUnited States, Canada, Germany, Hungary, Spain
-
ShireCompletedHealthy VolunteersUnited States
-
ShireTakeda Development Center Americas, Inc.No longer availableAngioedema | Hereditary Angioedema (HAE)United States, Canada, Germany, Hungary, Spain
-
Charite University, Berlin, GermanyShire International GmbHActive, not recruitingHereditary Autoinflammatory DiseaseGermany
-
Vanderbilt University Medical CenterRecruitingHemodialysis Complication | Hypotension of HemodialysisUnited States